All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

The Annual Report 2025, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance, operating and financial ...

MS doesn't always give a clear signal when it's evolving, so it's important to take a moment to reflect and listen to your body. Asking yourself a few questions can give you a clear view of how MS is ...

Novartis EPIC Commitments To sustain our progress, we renewed our EPIC pledge in 2023 to: remain committed to maintain gender representation in management (which seeks to ensure nondiscrimination and ...

Regulatory Compliance & Beyond We are addressing the trend of increasing regulations and support delivery on commitments to strengthen trust with society. Speed to Engagement Providing risk assurance ...

At Novartis, we reimagine medicine to improve and extend people’s lives. This includes discovering and developing breakthrough therapies and finding new ways to deliver these treatments to as many ...